DICLOFENAC POTASSIUM 50 MG + PARACETAMOL 325 MG TABLETS are a combination of oral solid dosage form with Diclofenac Potassium and Paracetamol as active pharmaceutical ingredients. Manufacturing of combination with dual active tablet involves a complex formulating challenge including compatibility of both ingredients, speed of mixing, tableting compression and final product stability. The active ingredients must be evenly distributed through the tablet matrix to allow reproducible pharmaceutical quality. For companies in to improve your PCD Pharma Franchise business, this combination range can be added to a set of oral solid dosage products with consistent specifications and packaging.
Each tablet of the formulation includes the following active pharmaceutical ingredients: Diclofenac Potassium 50 mg and Paracetamol 325 mg. As both active pharmaceutical ingredients possess different physicochemical properties, so the formulation development mainly concentrate to develop a compatible and stable tablet system.
Depending on the formulation technology chosen, it is possible to use appropriate excipients for tablet manufacturing such as diluents, binders, disintegrants, lubricants and glidants. The selection of each excipient is guided by their functional role and compatibility with the drug ingredients and desired tablet properties.
Compatibility studies will be carried out to support formulation development of the prepared products as Diclofenac Potassium, Paracetamol and the proposed excipient system. The formulation will be optimized for powder flow, compressibility, tablet strength, disintegration and dissolution.
The ultimate product should offer a consistent matrix within which both active constituents are evenly dispersed across the production run.
Uniformity of Blend Used by the manufacturer as an important consideration during manufacturing of DICLOFENAC POTASSIUM 50 MG + PARACETAMOL 325 MG TABLETS Since this formulation has two active ingredients in different strengths, it is important that powder be carefully blended.
Pre-blendrings The particles are often examined and categorised as part of the raw material inspection before blending. Sieving and milling may be included in production, when particle characteristics require it, to help secure an acceptable particle-size distribution.
Active ingredients and excipients may be pre-blended according to a specified manufacturing sequence. In the event of particle size and/or density differences that may cause segregation of the blend, addition may be controlled and appropriate mixing techniques used.
The uniformity testing of blends may be achieved by taking representative samples from different points within the blending. Analytical testing reveals whether or not the active ingredients are evenly dispersed prior to compression.
7. Controlled post-blend material movement The movement of material after mixing should also be controlled. This is to prevent further segregation of the material through excessive movement or relocation.
Once the powder mixture is ready, it is compressed into the required shape by suitable tablet press tools (dies and punches). The compression forces are determined during process development in line with the flow and compaction behaviour of the formulation.
Critical compression parameters might consist of: machine speed, compression force, feeder configuration, tooling configuration. These parameters can impact: tablet weight, thickness, hardness, friability, and disintegration.
In process The in-process check to monitor the weight and appearance of a tablet at defined intervals during the production of a batch. Other inprocess testing may include hardness, thickness and friability to verify mechanical uniformity.
If the final dosage form design requires, the formulation may also be manufactured as coated tablets. Then the coating conditions including the solvent system, spray rate, drying conditions and coating weight gain are carefully monitored to ensure an acceptable film coating.
Process optimization should lead to a reproducible compression process that yields tablets with uniform physical and chemical properties.
In-process control of DICLOFENAC POTASSIUM 50 MG + PARACETAMOL 325 MG TABLETS Quantity and quality of both active substances and finished drug product are controlled. Analyses may include, but are not restricted to, identity, assay and other relevant tests of chemical parameters by validated procedures.
Since two API ingredients are included in the formulation, the analytical methods should be valid for separate identification and quantification of the individual API ingredients. Related substances or degradation products can also be involved in the specification, as appropriate.
The physical quality of the product can be determined by aspect, average weight, variation of weight, hardness, friability and disintegration. The release of the active constituents can be analyzed by dissolution testing.
Content uniformity or alternative forms of uniformity testing may be appropriate, as required in the product specification. They may be necessary to demonstrate uniformity of individual tablets and between batches.
All testings are to be carried out in accordance with predefined test specifications and relevant pharmaceutical quality standards.
Stability testing is an important part of the development of the DICLOFENAC POTASSIUM 50 MG + PARACETAMOL 325 MG TABLETS. Stability studies can be performed to observe appearance, assay, dissolution, degradation marker assays and other relevant specifications for the product.
The choice of packaging should be determined by the nature of the formulation and the packaging system needs to address the protection of the tablets against damage during storage and transportation. The following may be considered: blister packs, strip packs and other relevant pharmaceutical pack sizes.
The type of packaging used needs to offer a sufficient barrier to protect the dosage form from light, moisture and other environmental factors if necessary. The compatibility of the formulation and the packaging can also be checked during product development.
Stability data can be useful in establishing storage conditions and justifying the proposed shelf-life. The outer final pack should bear approved product name, formulation, batch/serial numbers, manufacturing and expiry dates, storage instructions, as appropriate.
DICLOFENAC POTASSIUM 50 MG + PARACETAMOL 325 MG TABLETS or similar medicines can be part of a wide pharmaceutical portfolio of combination tablets, capsules, syrups, injections and topical products. Ensure a product range that is specific to your application and can be achieved with professional packaging.
For a PCD Pharma Franchise plan, the product need to offer with the right technical documentation, quality standards, packaging information, and authorized sales promotion material. The product display can effectively display the formulation name, active Ingredients, strength as well as packaging configuration, without any unsupported claims.
At every level of development from raw-material qualification to final package, the finished tablet's uniformity is ensured. Compatibility testing, stringent blending control, compression principles, testing, dissolution and stability testing and appropriate packaging all set the stage for a well-controlled manufacturing process for oral solid dosage forms.
Careful formulation and manufacture controls are needed as two active pharmaceutical ingredients are incorporated into a single uniform dosage form. Selection of materials, blend uniformity, compression, quality and stability controls is key to reproducible production and seamless integration into a professional pharmaceutical portfolio.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech